Moreover, since the mixed α1-, β1-, β2-AR antagonist, carvedilol, was more effective at preventing postoperative AF than the β1-antagonists metoprolol or atenolol [15, 23], this suggests the possibility of identifying specific mixed AR sub-type antagonism profiles for optimising rhythm control drug efficacy during adrenergic AF. This evidence concerns the gene AR and atrial fibrillation.